Document is current
Any future updates will be listed below
-
Authors
Buttler, Laura
Stange, Jan
Pyrsopoulos, Nikolaos
Hassanein, Tarek
Wedemeyer, Heiner
Maasoumy, Benjamin
Busch, Markus
,
Stange, Jan
Reich, David
Stein, Lance
Pyrsopoulos, Nikolaos
Cuervas-Mons, Valentin
Malik, Raza
Shah, Nikunj
Rossi, Simona
Caballeria, Juan
Subramanian, Ram
Duarte-Rojo, Andres
Thompson, Julie
Galle, Peter R.
Schmidt, Hartmut H.-J.
Busch, Markus
Chacko, Kristina
Adhami, Talal
Mobley, Constance
Kramer, David J.
Caldwell, Stephen
Al-Khafaji, Ali
Bhamidimarri, Kalyan R.
Romero-Gomez, Manuel
Hassanein, Tarek
Concepcion, Waldo
Castillo, Martin Prieto
Bañares, Rafael
Naqvi, Syed
Dollinger, Matthias
Krok, Karen
Stauber, Rudolf
Zauner, Christian
Lamprecht, Georg
Thuluvath, Paul
Aullo, Trinidad Serrano
-
Funding
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 20 November 2025
First Online: 8 December 2025
Declarations
:
: JS served as the Chief Medical Officer of Vital Therapies Inc. at the time of the VTL-308 study and is currently the Chief Medical Officer and Chairman of the Board of Albutec GmbH. HW served as a speaker/advisory board member for Abbott Laboratories & Abbott Molecular Inc., Bristol-Myers-Squibb, Gilead Sciences GmbH & Gilead Sciences Ltd., GlaxoSmithKline Services Unlimited, Janssen, Roche Diagnostics International Ltd., Vir Biotechnology, Inc.; received research support from Abbott Laboratories & Abbott Molecular Inc., Biotest AG; and received lecture fees from Biotest AG and Gilead Sciences GmbH & Gilead Sciences Ltd. BM served as a speaker and/or advisory board member for AbbVIe, AstraZeneca, Falk, Fujirebio, Gilead, Luvos, Merz, MSD, Norgine, Roche, W. L. Gore & Associates and received research support from Altona Diagnostics, EWIMED, Fujirebio, and Roche, all unrelated to the present work. LB, NP, TH and MB declare that they have no conflict of interest.
